Product Overview

Invokana 100 mg, known by its generic name canagliflozin, is a prescription oral antihyperglycemic agent indicated for the treatment of type 2 diabetes mellitus. Produced by Johnson & Johnson, the medication is formulated as a tablet containing 100 mg of the active ingredient and is packaged in strips of ten tablets. Available pack sizes include 30, 60, and 90 tablets, providing flexibility for patients with varying treatment durations. The drug is intended for once‑daily oral administration and should be used as an adjunct to a healthy diet and regular physical activity to achieve optimal glycemic control in adults diagnosed with type 2 diabetes.

What is Invokana 100 mg (Canagliflozin)

Invokana 100 mg represents the branded version of canagliflozin, a member of the sodium‑glucose co‑transporter‑2 (SGLT2) inhibitor class. By selectively blocking the SGLT2 protein in the proximal renal tubules, the drug reduces the reabsorption of filtered glucose, promoting its excretion through urine. This mechanism operates independently of insulin secretion, allowing the medication to lower blood glucose levels even in patients with impaired pancreatic beta‑cell function. The U.S. Food and Drug Administration (FDA) has approved Invokana for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and it is also indicated for cardiovascular risk reduction in certain patient populations.

Uses and Benefits

The primary therapeutic use of Invokana 100 mg is to lower circulating glucose concentrations in individuals with type 2 diabetes. Clinical trials have demonstrated that treatment can achieve reductions in hemoglobin A1C ranging from approximately 0.5% to 1.0% on average, depending on dosage and baseline disease severity. In addition to glycemic control, studies have shown modest improvements in body weight and systolic blood pressure, contributing to a more favorable metabolic profile. Moreover, cardiovascular outcome studies have revealed that Invokana can decrease the risk of hospitalization for heart failure and may provide protective effects against certain cardiovascular events in patients with existing heart disease, making it a comprehensive option for integrated diabetes management.

How It Works

Canagliflozin functions by inhibiting the SGLT2 transporter, a protein responsible for reabsorbing glucose from the urine back into the bloodstream. When this transporter is blocked, excess glucose is eliminated through urination, leading to a measurable decline in plasma glucose levels. The diuretic effect associated with increased urinary output can also contribute to modest weight loss and reductions in blood pressure. Because this mechanism does not rely on insulin signaling, Invokana remains effective in a broad range of patients, including those with insulin resistance or reduced endogenous insulin production.

Dosage Guidelines

The recommended initial dosage of Invokana 100 mg is one tablet taken once daily, with or without food. If additional glycemic control is required, a healthcare provider may consider increasing the dose to 300 mg once daily, but only after evaluating renal function and patient response. Patients with an estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m² should not use Invokana, as the drug’s efficacy and safety have not been established in this population. Consistent daily dosing is essential to maintain therapeutic benefit, and missed doses should be handled according to the instructions provided in the frequently asked questions section. For detailed prescribing information, refer to the FDA label: FDA Prescribing Information.

Side Effects

Like all pharmaceutical agents, Invokana 100 mg may be associated with adverse effects. The most frequently reported side effects include urinary tract infections, genital mycotic infections, and increased urinary frequency. Although rare, serious adverse events such as diabetic ketoacidosis and bone fractures have been documented, particularly in patients with predisposing risk factors. Patients should be advised to monitor for symptoms such as persistent nausea, vomiting, abdominal discomfort, unexplained fatigue, or signs of infection, and to contact their healthcare provider promptly if any of these occur.

Warnings and Precautions

Prior to initiating therapy with Invokana, patients should provide a complete medical history, focusing on kidney function, liver health, and any prior episodes of ketoacidosis. The medication is contraindicated in individuals with type 1 diabetes, patients who have exhibited hypersensitivity to canagliflozin, and those with severe renal impairment (eGFR < 45 mL/min/1.73 m²). Caution is recommended for elderly patients, individuals on diuretic therapy, and patients with conditions that predispose them to dehydration. Regular monitoring of renal function, electrolytes, and glycemic control is advised throughout treatment. For comprehensive safety information, consult the FDA prescribing information linked above. Additional guidance on diabetes management is available from the National Institute of Diabetes and Digestive and Kidney Diseases: NIDDK.

Drug Interactions

Invokana has the potential to interact with several classes of medications, including diuretics, certain antihypertensive agents, and drugs that affect renal function. Concomitant use with other SGLT2 inhibitors or insulin secretagogues may increase the risk of hypoglycemia, requiring dose adjustments. Additionally, medications that impair renal perfusion, such as non‑steroidal anti‑inflammatory drugs (NSAIDs), can alter the pharmacokinetics of canagliflozin and should be used with caution. For more detailed interaction data, refer to the FDA’s medication guide: FDA Medication Guide.

Storage and Handling

Store Invokana 100 mg tablets at room temperature, away from moisture and heat. Keep the medication in its original packaging until ready to use, and ensure that the strip is sealed properly after each use. Do not store the medication in the bathroom or near a sink where it could be exposed to excess humidity. Keep out of reach of children and pets. If a dose is missed, the patient should take it as soon as remembered unless it is close to the time of the next dose; in that case, the missed dose should be skipped and the regular dosing schedule resumed.

Monitoring and Follow‑up

Regular follow‑up visits are recommended to assess renal function, electrolytes, and overall glycemic control. Healthcare providers may order periodic urine tests to detect early signs of infection or ketoacidosis. Patients should be encouraged to report any new symptoms promptly and to undergo routine laboratory monitoring as directed. Adherence to these monitoring plans helps ensure the safe and effective use of Invokana over the course of treatment.

Frequently Asked Questions

1. What is the typical starting dose of Invokana? The usual starting dose is 100 mg taken once daily. Dosage adjustments may be made based on glycemic response and renal function.

2. Can Invokana be used in patients with cardiovascular disease? Yes. Clinical data indicate that Invokana can reduce the risk of hospitalization for heart failure and may provide cardiovascular benefits in patients with type 2 diabetes and established heart disease.

3. How does Invokana differ from other oral diabetes medications? Unlike medications that stimulate insulin secretion, Invokana lowers glucose by increasing urinary glucose excretion, offering a distinct mechanism and potential cardiovascular advantages.

4. Does Invokana cause weight loss? Yes, patients often experience modest weight reduction, typically 2–5 kg over several months, due to caloric loss through urine.

5. What should I do if I miss a dose? Take the missed dose as soon as you remember, unless it is near the time of the next scheduled dose; in that case, skip the missed dose and continue with your regular schedule.

Related Products

• Okamet 500 Mg (Metformin)
• Imbruvica 140 mg (Ibrutinib)
• Glimepiride 2 mg (Generic)
• Glimepiride 1 mg (Generic)
• Glycomet-GP 0.5 Forte (Metformin/Glimepiride)
• Glycomet-GP 0.5 Tablet (Metformin/Glimepiride)
• Forxiga 5mg (Dapagliflozin)
• Glycomet-GP 1 Tablet (Metformin/Glimepiride)
• Amaryl M 1mg (Metformin/Glimepiride)
• Glycomet-GP 2 Forte (Metformin/Glimepiride)
• Glycomet-GP 1 Forte (Metformin/Glimepiride)
• Glimepiride 4 mg (Generic)